

Datasheet: HCA237P

Description:	HUMAN ANTI OMALIZUMAB (DRUG/TARGET COMPLEX):HRP		
Specificity:	OMALIZUMAB DRUG/TARGET COMPLEX		
Format:	HRP		
Product Type:	Monoclonal Antibody		
Clone:	AbD20760_hlgG1		
Isotype:	lgG1		
Quantity:	0.1 mg		

Product Details

Applications	This product has been re derived from testing with communications from the information. For general rad-antibodies.com/proto	in our labo e originato protocol re	oratories, j rs. Please	peer-reviewed publicates in the publicates in th	tions or personal dicated for further
		Yes	No	Not Determined	Suggested Dilution
	ELISA	•			1/200 - 1/2000
	Where this product has r necessarily exclude its u a guide only. It is recomr system using appropriate	se in such mended th	procedur at the use	es. Suggested working or titrates the product f	g dilutions are given as
Product Form	Human IgG1 antibody (k and expressed in a huma liquid.				
Preparation	Purified IgG prepared by	affinity ch	romatogra	aphy on Protein A	
Source	НКВ-11				
Buffer Solution	Phosphate buffered salin	ie			
Preservative Stabilisers	0.0095% MIT				
Approx. Protein Concentrations	IgG concentration 1.0 mg	g/ml			
Immunogen	Omalizumab/IgE comple	x			
Specificity	Human anti omalizuma	b, clone A	AbD20760	_hlgG1 binds specific	cally to the

omalizumab/IgE (drug/target) complex. The antibody does not recognize free omalizumab or free human IgE. It can be used in bioanalytical assays to detect bound omalizumab or biosimilar products exclusively.

Clone AbD20760_hIgG1 can be used to develop a pharmacokinetic (PK) antigen capture assay to measure omalizumab captured via immobilized human IgE or to measure the level of drug/IgE complex in preclinical or clinical samples. This product is in a full immunoglobulin format and is available directly labeled with HRP. The antibody is also available in unlabeled Fab format (HCA238).

Omalizumab (brand name Xolair[®]) is a recombinant DNA-derived humanized IgG1 kappa monoclonal antibody used in the treatment of patients with moderate or severe asthma who have demonstrated a positive allergy skin test and whose symptoms are not controlled by inhaled corticosteroids.

Allergic asthma is mediated by IgE released by B cells in response to allergen. Circulating IgE binds to the high-affinity IgE Fc receptor (Fc ϵ RI) expressed on basophils and mast cells, triggering the release of histamine, leukotrienes and other mediators associated with the pathophysiology of asthma. Omalizumab is directed against the Fc region of human immunoglobulin E (IgE). By binding to circulating IgE at the site of Fc ϵ RI binding, this therapeutic antibody prevents the interaction of IgE with its receptor thus limiting mediator release. Treatment with omalizumab has also been demonstrated to reduce the expression of Fc ϵ RI on mast cells and basophils, providing additional clinical benefit.

View a summary of all anti-omalizumab antibodies

Affinity	The intrinsic affinity of the monovalent form of this antibody is $K_D = 0.58$ nM as measured by real time, label free molecular interaction analysis on immobilized omalizumab in complex with human IgE.
ELISA	This product may be used in a direct ELISA to detect the omalizumab/IgE complex or to detect omalizumab bound to immobilized IgE. Protocol: <u>PK antigen capture ELISA to measure bound drug exclusively</u> .
References	1. Harth, S. <i>et al.</i> (2019) Generation by phage display and characterization of drug-target complex-specific antibodies for pharmacokinetic analysis of biotherapeutics. <u>MAbs. 11 (1):</u> <u>178-190.</u>
Storage	This product is shipped frozen. When ready to use, thaw and aliquot the sample as needed. Store aliquots at -70°C, if available, otherwise store at -20°C. It is not recommended to keep aliquots at 4°C for more than one week.
Guarantee	12 months from date of despatch.
Acknowledgements	This product and/or its use is covered by claims of U.S. patents, and/or pending U.S. and non-U.S. patent applications owned by or under license to Bio-Rad Laboratories, Inc. See bio-rad.com/en-us/trademarks for details.

Health And Safety Information	Material Safety Datasheet documentation #20479 available at: https://www.bio-rad-antibodies.com/SDS/HCA237P		
Licensed Use	For <i>in vitro</i> research purposes and for commercial applications for the provision of <i>in vitro</i> testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.		
Regulatory	For research purposes only		
Technical Advice	Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the <u>HuCAL Antibodies Technical Manual</u> .		

Related Products

Recommended Useful Reagents

HISPEC ASSAY DILUENT (BUF049A) RECOMBINANT HUMAN IgE KAPPA (HCA190) RECOMBINANT HUMAN IgE LAMBDA (HCA171) HUMAN ANTI OMALIZUMAB (DRUG/TARGET COMPLEX) (HCA238) HUMAN ANTI OMALIZUMAB (HCA236) HUMAN ANTI OMALIZUMAB (HCA235)

Product inquiries: www.bio-rad-antibodies.com/technical-support

To find a batch/lot specific datasheet for this product, please use our online search tool at: bio-rad-antibodies.com/datasheets 'M432731:240912'

Printed on 10 Jul 2025

© 2025 Bio-Rad Laboratories Inc | Legal | Imprint